N@N

Michael G. King, Jr., Re-Joins Rodman & Renshaw as Managing Director and Senior Biotechnology Analyst

^{Published on 2011-07-11 07:05:38 - Market Wire}
 

NEW YORK--([ BUSINESS WIRE ])--Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), today announced that Michael G. King, Jr., has rejoined the firm in the position of Managing Director and Senior Biotechnology Analyst, bringing his extensive sell-side experience as a biotechnology industry analyst to Rodman.

"Mike has a long and distinguished career in biotechnology research, and we are pleased to have him back in the fold and contributing to our efforts to service our clientele as best we can."

aWe are delighted to have Mike back at Rodman, doing what he does best-advising our buy side clients as to what decisions they should be making with regard to their investments in the biotechnology space,a said Edward Rubin, Chief Executive Officer of Rodman & Renshaw. Rubin continued, aMike has a long and distinguished career in biotechnology research, and we are pleased to have him back in the fold and contributing to our efforts to service our clientele as best we can.a

aIta™s great to be back at Rodman again, the place where I produced the best research of my career,a said Mr. King. aRodman has changed in multiple positive ways since I was last here. However, one thing has remained constant - the firma™s unwavering focus on biotechnology companies and the investors who help fund the development of their medicines. I am very much looking forward to launching coverage in the near term.a

Mr. King has over 17 years of experience as a leading biotechnology equity research analyst, consistently ranking at the top of Institutional Investor magazine's annual sell-side research survey in addition to being named that publication's "Home Run Hitter" in 2000. Most recently, Mr. King served as Senior Vice President of Corporate Development and Communication at ZIOPHARM Oncology (NASDAQ: ZIOP), a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics. Prior to joining ZIOPHARM, Mr. King was a Managing Director and Senior Biotechnology Analyst at Wedbush Securities. Prior to that, Mr. King was a Managing Director and Senior Biotechnology Analyst at Merriman Curhan Ford with other prior positions at leading firms including Dillon Read, Vector Securities International, Robertson Stephens, Banc of America Securities and Rodman & Renshaw, where he was Director of Research. Mr. King began his career in finance in sales at Kidder Peabody.

About Rodman & Renshaw, LLC

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of deal volume of PIPE and RD financing transactions completed every year since 2005.

For more information visit Rodman & Renshaw on the Internet at [ www.rodm.com ].

MEMBER FINRA, SIPC